The company's leading candidate, CRV431, is currently in phase 1 of clinical trials and targets multiple biochemical pathways involved in the progression of liver disease, including fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. Preclinical studies have shown promising results, with reductions in liver inflammation, fibrosis, and cancerous tumors. CRV431 also exhibits antiviral activity against hepatitis B, C, and D viruses.